Topics

Novartis’ Mayzent could preserve mobility in MS patients

07:09 EDT 12 Sep 2019 | PharmaTimes

The average time to when patients require a wheelchair could be extended from 12 years to 16.3 years.

Original Article: Novartis’ Mayzent could preserve mobility in MS patients

NEXT ARTICLE

More From BioPortfolio on "Novartis’ Mayzent could preserve mobility in MS patients"

Quick Search